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Aim: To study the cytostatic and some biological effects of aminoferrocene using mice with L1210 lymphoid leukemia. Materials and 
Methods: Experiments were performed on BDF1 male mice (DBA/2, female × C57Bl/6, male) with transplantable L1210 lymphoid 
leukemia. Determination of antitumor activity of Benzyl-Fc Boron (Bn), it was injected intraperitoneally 6 times daily, starting 
on day 2 after L1210 leukemia cell transplantation. Doses of Bn such as 26; 260 and 2600 μg/kg were used. The determination 
of intracellular content of cardiolipin, thiols, reactive oxygen species (ROS) and also analysis of Annexin V positivity and mitochon-
drial transmembrane potential (JC-1 staining) were performed with use of flow cytometry. The levels of “free iron” complexes, 
transferrin active forms and the rate of NO generation were measured by EPR-specroscopy. Results: Six daily injections of Bn at a dose 
of 26 μg/kg resulted in an increased survival of mice with L1210 leukemia by 28% (p < 0.05). Bn led to an increase of apoptotic cells 
number and ROS amount in leukemia cells. Besides, Bn caused a decrease of cardiolipin and nonprotein thiol compounds content. 
The membrane electrochemical potential of cell mitochondria was decreased also after Bn administration. Studies using EPR-spec-
troscopy revealed a significant increase in a level of “free iron”, content of transferrin active species and generation rate of NO by in-
ducible NO-synthase in L1210 cells after aminoferrocene administration. Conclusion: Our data indicate that Benzyl-Fc Boron can 
be promising candidate for realizing a new strategy of anticancer therapy with the use of ROS-inducing agents.
Key Words: aminoferrocene, tumor, L1210 leukemia, mitochondria membrane electrochemical potential, cardiolipin, thiols, ROS, 
transferrin, NO-generation.
In the last decade, some publications have ap-
peared showing an antitumor activity of ferrocene 
and its derivatives [1–9]. It has been shown that the 
representatives of these compounds exhibit cyto-
toxic activity in vitro and lead to retardation of some 
ascitic tumors growth [9, 10]. According to data 
of several authors, an antitumor effect of ferrocene 
and its derivatives is achieved through the production 
of H2O2 and hydroxyl radicals [1, 2, 9]. Other research-
ers suggest that this effect is realized by the activation 
of the immune system [1, 10] or due to the influence 
on estrogen receptors in the case of breast cancer 
cells [11]. Moreover, the complexes of ferrocene and 
its derivatives with biologically active molecules [12–
16], retinoids [17, 18], hormones and hormone an-
tagonists [19], metals such as Co, Cu, Zn, Pt, Pd, Rh, 
Ir [20–25], are sometimes used as anticancer agents. 
For example, aminoferrocene-based prodrugs were 
found to exhibit significant toxicity towards a range 
of cancer cell lines (HL-60, JVM-2, BL-2, Raji, HeLa, 
PANC-1, SK-OV-3, U-373, LNCaP, DU-145, RKO) 
and primary cancer cells (CLL cells), whereas their 
effect on normal (non-cancerous) cells including 
mononuclear cells (MNC’s) and fibroblasts was found 
to be limited [26, 27]. Moreover, it has been demon-
strated that aminoferrocenes are activated in the pre-
sence of elevated concentrations of reactive oxygen 
species (ROS), which are conditions characteristic for 
cancer cells [9]. However, no in vivo studies of these 
promising prodrugs have been reported up to date.
Owing to the above-mentioned, the objective of our 
work was the study of antitumor activity of the ami-
noferrocene-based prodrug N-ferrocenyl-N-benzyl-
aminocarbonyloxymethyl-phenylboronic acid pinacol 
ester (briefly Bn) and the study of the mechanism of its 
action on L1210 murine lymphoid leukemia models. 
Since Bn is the donor of iron, we have studied some 
of the indicators that characterize the state of the in-
tracellular ROS/antioxidants balance.
MATERIALS AND METHODS
Synthesis of Bn. N-Ferrocenylaminocarbonyloxy-
methylphenyl boronic acid pinacol ester (compound 1, 
50.0 mg, 108 μmol) was dissolved in anhydrous DMF 
(2 ml) under a nitrogen atmosphere. The solution was 
treated with NaH (5.20 mg, 130 μmol, 60% mineral oil 
suspended) and stirred 30 min at 22 °C. Benzyl bromide 
(27.8 mg, 19.3 μl, 163 μmol) was added and the reac-
tion was stirred for 2 h at 22 °C. Then, the solvent was 
removed in vacuum (0.01 mbar) and the product was 
purified by column chromatography on silica gel using 
petroleum ether/acetone (4/1, v/v) as eluent. Yield: 
55 mg, 100 μmol (92%). TLC (SiO2, eluent petroleum 
ether/acetone, 4:1, v/v) Rf = 0.5; 1H-NMR (aceton-d6, 
300 MHz) δ (ppm) 7.73 (d, 2 H), 7.39–7.27 (m, 7 H), 
5.25 (s, 2 H), 5.02 (s, 2 H), 4.46 (s, 2 H), 4.12 (s, 5 H), 
3.97 (s, 2 H), 1.34 (s, 12 H). The spectra are in agree-
ment with those reported for this compound.
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All in vivo experiments were performed in compli-
ance with all the requirements of biological ethics 
on BDF1 male mice (DBA/2, female × C57Bl/6, male) 
weighing 20–22 g and bred in vivarium of the R.E. Ka-
vetsky Institute of Experimental Pathology, Oncology 
and Radiobiology of NAS of Ukraine. The animals were 
kept under standard laboratory conditions: in poly-
styrene cages, coated with galvanized steel mesh, 
the room temperature was 20–22 °С, air humidity — 
60–70%.
Firstly Bn was dissolved in DMSO at 37 °C. Then, 
a certain amount of PBS was added to obtain the de-
sired concentration of Bn. While determining the acute 
toxicity indices (MTD and LD50) Bn was injected intra-
peritoneally at a single dose of 10; 50; 100; 150; 200; 
300; 400; 500; 700; 1000; 1500; 3000, and 6000 μg/kg. 
6 mice were used to evaluate each dose. Animals were 
kept under observation for 3 weeks.
While determining the antitumor activity of Bn, 
it was injected intraperitoneally 6 times daily,  starting 
on day 2 after transplantation of L1210 lymphoid 
leukemia. L1210 was transplanted intraperitoneally 
in the amount of 1•106 cells per mouse. After the trans-
plantation all of the animals were divided into 4 groups 
(10 mice in each): I — tumor control (intraperitoneal in-
jection of 0.4 ml of saline); II — injection of Bn at a dose 
of 26 μg/kg; III — injection of Bn at a dose of 260 μg/kg; 
IV — injection of Bn at a dose of 2600 μg/kg.
To evaluate the mechanism of Bn action it was in-
jected only in the dose that was effective at determina-
tion of average lifetime of animals. There were 5 mice 
in each group, including the control one. The injection 
of Bn started 24 hours after L1210 cells transplanta-
tion. 6 daily intraperitoneal injections were performed. 
An ascites was washed out from the abdominal cavity 
and determination of the number of apoptotic cells, 
cardiolipin and non-protein thiol compounds content, 
mitochondria functional activity (JC-1) and the amount 
of ROS in cells were performed one day after the last 
injection of Bn.
Measurement of Annexin V and propidium 
iodide (PI) positivity. Translocation of phosphatidyl-
serine from the inner to the outer leaflet of the plasma 
membrane occurs during apoptosis and can be as-
sessed by exploiting the high binding affinity of An-
nexin V, a Ca2+-dependent phospholipid binding protein 
to phosphatidylserine. To examine whether cell death 
occurred via apoptosis or necrosis, PI, a non-permeable 
stain with affinity towards nucleic acids, which selec-
tively enters necrotic or late apoptotic cells, was used. 
Therefore, costaining of Annexin V and PI helps dis-
criminate between live cells (PI and Annexin V negative), 
cells in early apoptosis (Annexin V positive, PI nega-
tive), cells undergoing late apoptosis (both Annexin 
V and PI positive) or necrotic cells (PI positive, Annexin 
V negative). For detection of apoptotic cells we used 
apoptosis detection kit (Annexin V-FITC kit, Beck-
man Coulter, USA). Briefly, L1210 cells (2.5•105/ml) 
after two washes, cells were resuspended in An-
nexin V binding buffer (10 mM HEPES/NaOH, pH 7.4, 
140 mM NaCl, 2.5 mM CaCl2) and Annexin V-FITC 
was added ac cording to the manufacturers’ instruc-
tions. The cells were incubated for 10 min in the dark 
at 37 °C and just 5 min prior to acquisition, PI (0.1 mg/
ml) was added and cells were washed and placed then 
in a flow cytometer (Beckman Coulter Epics XL, USA).
Measurement of cardiolipin content. To deter-
mine the cardiolipin content in mitochondria, 10-N-no-
nyl acridine orange (NAO) was used. Briefly, L1210 cells 
(2.5•105/ml) were washed with PBS, labeled with 
NAO (100 nM in methanol, 37 °C, 20 min), acquired 
at FL1 channel and analyzed in a flow cytometer.
Analysis of mitochondrial transmembrane 
potential. The mitochondrial transmembrane elec-
trochemical gradient (Dym) was measured using 
JC-1. JC-1, a cell permeable, cationic, lipophilic dye 
freely crosses the mitochondrial membrane and forms 
J-aggregates which fluoresce red; accordingly, viable 
cells with a normal mitochondrial membrane potential 
when stained with JC-1 exhibit a pronounced orange 
fluorescence (FL2). Following an apoptotic stimulus, 
the resultant decrease in the mitochondrial membrane 
potential prevents JC-1 from entering the mitochondria 
and remains as monomers in the cytosol that emits 
a predominantly green fluorescence (FL1). Therefore, 
the ratio of J-aggregates/monomers serves as an ef-
fective indicator of the cellular mitochondrial transmem-
brane potential, allowing apoptotic cells to be easily 
distinguished from their non-apoptotic counterparts. 
Briefly, L1210 cells (2.5•105/ml) were stained with 
JC-1 (7.5 mM in PBS, 10 min, 37 °C). Cells were then 
acquired in a flow cytometer on the basis of quadrant 
plot to distinguish monomers from J-aggregates. To set 
the quadrants, cells were treated with H2O2 (20 mM, 
37 °C, 30 min), representative of cells with depolarized 
mitochondrial membrane potential.
Flow cytometric determination of intracellular 
thiols. Non-protein thiols were measured. L1210 cells 
(2.5•105/ml) were washed, resuspended in PBS and 
labelled with CMFDA (0.05 mM, 37 °C, 20 min). CMFDA 
is a cell permeable, non-fluorescent dye that upon en-
tering the cell, rapidly binds with non-protein thiols and 
becomes non-permeable. The simultaneous cleavage 
of the diacetate moiety by cellular esterases yields 
a fluorescent thioether whose fluorescence is acquired 
in a flow cytometer at FL1 channel.
Measurement of intracellular ROS. CM-
H2DCFDA, a lipid soluble membrane permeable dye 
upon entering cells undergoes deacetylation by in-
tracellular esterases and forms the more hydrophilic, 
non-fluorescent dye Dichlorodihydrofluorescein 
(DCFH2). This is subsequently oxidized by ROS with 
formation of a highly fluorescent oxidation product, Di-
chlorofluorescein (DCF). The generated fluorescence 
is directly proportional to the amount of ROS. Fluo-
rescence was analyzed by flow cytometry. The effect 
of Bn on generation of ROS was measured in L1210 cell 
(2.5•105 cells). After centrifugation (1500 rpm for 
5 min) cells were resuspended in PBS, incubated for 
30 min at 37 °C with CM-H2DCFDA (10 mM) for measu-
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rement of ROS. Positive control with 25 μM H2O2 was 
also made (data not presented). Fluorescence was 
acquired in the log mode and expressed as geometri-
cal mean fluorescence channel (GMean). Acquisition 
was performed on 10,000 gated events.
Determination of “free iron” complexes, the con-
tent of active forms of transferrin and the rate 
of NO generation. Levels of transferrin and “free iron” 
in L1210 leukemia cells were measured by EPR-spec-
troscopy method at the temperature of liquid nitrogen 
(77 K). The speed of generating NO by iNOS (inducible 
NO-synthase) was also measured by EPR method using 
a spin trap DETK (Sigma) at a room temperature.
Main blood indices of mice was investigated by the use 
of a haematological analyzer Particle Counter PCE-
210 (Erma Inc., Japan). Statistical processing of the data 
was performed by the use of the software Statistica 
v. 7.0 and Student’s t-criterion. A statistically significant 
difference was considered to be present at p < 0.05.
RESULTS AND DISCUSSION
Synthesis of 4-(N-ferrocenyl-N-benzyl-
aminocarbonyloxymethyl)-phenylboronic acid 
pinacol ester. We previously reported a procedure 
for preparation of compound Bn under optimized 
conditions (Fig. 1). In particular, we used com-
pound 1 as a starting material which can be obtained 
from commercially available starting materials in large 
quantities with 74% yield [28]. Compound Bn was 
alkylated in the presence of Cs2CO3 using BnCl/
(NBu4)I mixture as an electrophile. This procedure 
led to clean conversion of 1 into Bn with 71% yield 
of the analytically pure product. However, due to the low 
solubility of the (NBu4)I in the column chromatography 
eluent it was necessary to adsorb the crude reaction 
mixture onto silica. Unfortunately, this led to visible 
decomposition on dry silica which explains the yield 
of 71%, despite full conversion to the product.
Fig. 1. Outline of the previously reported method of synthesis 
of compound Bn [28]
For further optimization of the synthesis, an alterna-
tive approach to Bn was developed (Fig. 2). It consisted 
of the alkylation of 1 in the presence of NaH  using 
either benzyl chloride or bromide as electrophiles. 
This procedure led again to clean conversion of 1 into 
Bn. However, it was possible to dissolve the crude 
reaction mixture in the appropriate eluent for column 
chromatography. Therefore adsorption on silica was 
not necessary. This led to an isolated yield of analyti-
cally pure Bn with a yield of 92%.
Fig. 2. Outline of the optimized method of synthesis of compound Bn
Biological studies. At the first stage of the in-
vestigation an acute toxicity of Bn was studied. That 
is, it was necessary to determine the maximum tole-
rated dose (MTD) and the lethal dose which causes 
the death of animals in 50% (LD50) at a intraperito-
neal injection. For this purpose the BDF1 hybrid mice 
(DBA/2, female × C57Bl/6, male) were used, which 
were injected intraperitoneally with Bn at a single dose 
of 10; 50; 100; 150; 200; 300; 400; 500; 700; 1000; 
1500; 3000, and 6000 μg/kg. All the above-stated 
doses of Bn were non-toxic (i.e., all of the mice were 
alive after Bn injection) (Table 1).
Table 1. Data on the study of acute toxicity of Bn on BDF1 hybrid mice
Dose of Bn, 
μg/kg
Number of ani-
mals per group
Number of alive 
animals
Number of dead 
animals
10 6 6 0
50 6 6 0
100 6 6 0
150 6 6 0
200 6 6 0
300 6 6 0
400 6 6 0
500 6 6 0
700 6 6 0
1000 6 6 0
1500 6 6 0
3000 6 6 0
6000 6 6 0
At the second stage of studies an antitumor activity 
of Bn in relation to the L1210 leukemia was investiga-
ted. The studies found that the injection of Bn at a dose 
of 26 μg/kg resulted in an increase of mice lifetime 
by 28% (Table 2, Fig. 3). Such doses of Bn as 260 and 
2600 μg/kg were ineffective. It should be noted that 
the increase in the number of past days by 28% for 
mice with ascitic lymphoid leukemia L1210 should de-
serve attention, as a minimum percentage of the effect 
for the positive assessment is the increase of lifetime 
by 25% [29].
Table 2. Number of past days (days of survival) after L1210 cells trans-
plantation
Group of mice with L1210 Number of past days
I (control), n = 10 13.7 ± 0.6
II (Bn; 26 μg/kg), n = 10 17.5 ± 0.7*
III (Bn; 260 μg/kg), n = 10 14.7 ± 0.5
IV (Bn; 2600 μg/kg), n = 10 13.7 ± 0.6
Note: *р<0.05 compared with control mice.
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Fig. 3. Mice lifetime after L1210 cells transplantation (Kaplan — 
Meier survival curves)
In order to identify the mechanism of Bn action 
in the control mice and animals injected with Bn at a dose 
of 26 μg/kg, the ascites was washed out from their ab-
dominal cavity. After that, the determination of the num-
ber of apoptotic cells, cardiolipin and non-protein thiol 
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compounds content, mitochondria functional activity 
(JC-1) and the amount of ROS in cells was performed.
As a result of studies, it was found that 6 daily injec-
tions of Bn at a dose of 26 μg/kg led to an increase 
in the amount of apoptotic cells from 5.24 ± 0.3 to 8.0±0.4% 
(p < 0.05) (Fig. 4). Besides, Bn caused a decrease 
of cardiolipin content in ascitic cells (Fig. 5). Whereas 
in the control group a level of fluorescence gave a value 
of 150.3 ± 10.5 arbitrary units (a.u.), in the group injected 
with Bn it was 104.1 ± 13.1 a.u. (р < 0.05). Cardiolipin 
is known to be a very important phospholipid of an inner 
mitochondrial membrane and is involved in ensuring 
a coupling of oxidative phosphorylation process.
The fluorescence of the dye JC-1 also indicates 
a deterioration of a mitochondria functional state 
(Fig. 6). The fluorescence of JC-1 indicates the total 
value of the membrane electrochemical potential of all 
mitochondria of the studied cells. The index of green 
fluorescence (JC-1 monomers) in the control group was 
48.2 ± 3.1% and after Bn administration it was 97.0 ± 
4.3% (p < 0.05).
An important stage in the study was an evaluation 
of so-called “redox state” of ascitic cells. For this pur-
pose we have determined a content of non-protein thiol 
compounds (glutathione content practically). Bn led 
to a decrease of this index in ascitic cells: the level 
of fluorescence in cells after Bn administration was 
132.4 ± 12.5 a.u. and 174.9 ± 15.0 a.u. in the control 
group (р < 0.05) (Fig. 7). This data conformed well with 
the results of the ROS determination in cells (Fig. 8). 
In the control group the level of fluorescence was 
163.3 ± 20.0 a.u., while after Bn administration it was 
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Fig. 4. Alteration of the number of L1210 cells undergoing apoptosis and necrosis after Bn administration. In order from left to right: 
1 — control without colour, 2 — cells of the animal from the control group, 3 — cells of the animal administered with Bn
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Fig. 5. The content of cardiolipin in L1210 cells after Bn administration (flow cytometry). On the left — Dot Plot, the cells are dis-
tributed by size and granularity. We can see two cell populations. On the right: black — unpainted control, blue — control cells, 
red — cells from the animal administered with Bn
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Fig. 6. Alteration in the mitochondria membrane electrochemical potential of L1210 cells after Bn administration (flow cytometry). 
In order from left to right: 1 — control without colour, 2 — cells of the animal from the control group, 3 — cells of the animal admini-
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230.0 ± 18.5 a.u. (р < 0.05). In fact, a reduction of non-
protein thiol compounds is accompanied by an increase 
in the amount of ROS.
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Fig. 7. The content of non-protein thiol compounds in L1210 cells 
after Bn administration (flow cytometry). Black — unpainted 
control, blue — control cells, red — cells of the animal admi-
nistered with Bn
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Fig. 8. The content of ROS in L1210 cells after Bn administration 
(flow cytometry). Black — unpainted control, blue — control 
cells, red — cells of the animal administered with Bn
Another direction in the investigation of bio-
logical effects of Bn was an assessment of its impact 
on the number of haematological indices. Therefore, 
main blood indices of the animals with L1210 were 
determined. It was found that a clear tendency to re-
duction in the total number of leukocytes in the mice 
peripheral blood was fixed after a 6 times daily Bn in-
jection (Table 3). Moreover, such decrease occurs 
due to the reduction in the number of lymphocytes. 
The total number of erythrocytes, thrombocytes and 
haemoglobin level in the blood of mice received Bn, 
did not differ from the blood indices of control animals.
Table 3. Main peripheral blood indices of mice with L1210 after a course 
of Bn therapy
Indexes Control (n = 5) Bn (n = 5)
Number of erythrocytes, ×109/ml 10.5 ± 0.4 9.9 ± 0.4
Haemoglobin level, g/dl 15.7 ± 0.6 14.7 ± 0.7
Number of thrombocytes, ×106/ml 485.0 ± 67.3 496.0 ± 37.6
Total leukocytes, ×106/ml 18.0 ± 2.0 14.4 ± 1.3
Number of lymphocytes, ×106/ml 9.8 ± 1.1 5.6 ±0.8*
Number of monocytes, ×106/ml 2.7 ± 0.2 2.9 ± 0.3
Number of granulocytes, ×106/ml 5.5 ± 0.8 5.9 ± 0.6
Note: *р < 0.05 compared with the control group.
Seemingly, an important part in the mechanism 
of Bn action is its influence on cardiolipin. It is be-
lieved that this phospholipid can integrate elements 
of the mitochondria respiratory chain in an integral 
complex [30]. It has been found that the peroxide 
degradation of cardiolipin stimulates a release of cy-
tochrome C from mitochondria into the cytoplasm, 
and this process is associated with apoptosis [31]. 
In general, most studies support the idea that car-
diolipin directly initiate apoptosis [32, 33]. Even there 
is a hypothesis that an interaction between cardiolipin 
and cytochrome C deteriorates before apoptosis start, 
and this leads to the mitochondrial membrane perme-
abilization [34]. In addition, cardiolipin supports mito-
chondrial membrane potential at the required level.
Studies using EPR-spectroscopy revealed a signifi-
cant increase in a level of “free iron”, content of transferrin 
active species and generation rate of NO by inducible 
NO-synthase in L1210 cells after aminoferrocene ad-
ministration, compared with the control group (Table 4). 
Such alterations in L1210 cells may lead to an increase 
in generation of ROS and blocking of Fe-S protein centers 
in mitochondrial electron transport chain, which initiated 
cell death caused by necrosis or apoptosis.
Table 4. The level of “free iron” and transferrin active species, the rate 
of NO generation in L1210 cells after aminoferrocene administration
Index Control (n = 5)
Aminoferro-
cene (n = 5)
“Free iron”, a.u. 0.80 ± 0.10 2.16 ± 0.18*
Content of transferrin active species, a.u. 0.19 ± 0.02 0.37 ± 0.03*
NO generation rate (nmol/2.5•105 cells) 0.40 ± 0.04 0.77 ± 0.06*
Note: *р < 0.05 compared with the control group.
Thereby, the indices which we determined in this 
study are complementary. Bn leads to a generation 
of ROS in L1210 cells. And this is accompanied by a de-
crease of non-protein thiol compounds, which have 
a leading role in protection of proteins, lipids, nucleic 
acids in cells from oxidative stress. During the process 
of activation of free radical oxidation the cardiolipin 
becomes oxidized releasing cytochrome C and making 
its transfer into the cytoplasm possible. After release 
into the cytoplasm, it forms a complex with apoptosis-
inducing factor (Apaf-1) and procaspase-9 that acti-
vates downstream caspases, which carry out apoptotic 
cell death. Therefore, our data indicate that aminofer-
rocenes, particularly Bn, can be promising candidates 
for realizing a new strategy of anticancer therapy with 
the use of ROS-inducing agents. Aminoferrocenes are 
modern direction of redox-biotechnology.
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